HomePLX • NYSEAMERICAN
add
Protalix Biotherapeutics Inc
Previous close
$0.91
Day range
$0.90 - $0.94
Year range
$0.82 - $1.99
Market cap
69.45M USD
Avg Volume
166.05K
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 13.47M | -61.59% |
Operating expense | 6.44M | -24.23% |
Net income | -2.20M | -111.39% |
Net profit margin | -16.35 | -129.65% |
Earnings per share | — | — |
EBITDA | -2.11M | -110.18% |
Effective tax rate | 3.04% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 45.03M | -6.55% |
Total assets | 91.54M | 3.53% |
Total liabilities | 62.96M | 27.41% |
Total equity | 28.58M | — |
Shares outstanding | 73.54M | — |
Price to book | 2.33 | — |
Return on assets | -6.69% | — |
Return on capital | -10.94% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -2.20M | -111.39% |
Cash from operations | -3.61M | -172.59% |
Cash from investing | -180.00K | 18.92% |
Cash from financing | — | — |
Net change in cash | -3.81M | -125.15% |
Free cash flow | -3.87M | -791.03% |
About
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. Wikipedia
CEO
Founded
1993
Headquarters
Website
Employees
208